Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Respiratory Syncytial Virus Vaccine Market Growth Potential: How Will Market Size Shift Through 2030?
The respiratory syncytial virus vaccine market size has experienced robust growth in recent years. This market is projected to expand from $1378.59 million in 2025 to $1482.18 million in 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. Historical expansion can be linked to factors such as the increasing occurrence of RSV-related hospital admissions, the existing unmet medical requirement for infant immunization, heightened understanding of respiratory viral infections, public health monitoring of seasonal RSV outbreaks, and the expansion of clinical trials.
The respiratory syncytial virus vaccine market is projected to experience robust expansion over the forthcoming years. Its valuation is anticipated to reach $1957.68 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This growth during the projected timeframe is largely driven by factors such as the increasing authorization of new RSV vaccines, augmented governmental funding for immunization, greater uptake among older demographics, the broadening scope of preventive health initiatives, and a heightened emphasis on developing combination vaccines. Key trends anticipated throughout the forecast period involve the escalating creation of RSV vaccines tailored for high-risk groups, an intensified focus on immunization programs for both children and the elderly, increasing capital allocation towards sophisticated vaccine compositions, the widening reach of vaccination drives conducted in hospitals, and a stronger commitment to sustained RSV prevention strategies.
Get A Free Sample Report With In-Depth Market Insights:
Respiratory Syncytial Virus Vaccine Market Demand Drivers Opening New Revenue Streams
The escalating occurrence of respiratory infections is projected to stimulate the expansion of the respiratory syncytial virus vaccine market moving forward. Respiratory infections are conditions caused by viruses, bacteria, or other pathogens that impact the respiratory system, including areas like the sinuses, throat, airways, or lungs. This increasing incidence of respiratory infections is propelled by factors such as air pollution, climate change, greater urbanization, aging populations, and the emergence of drug-resistant pathogens. The respiratory syncytial virus (RSV) vaccine helps to lessen the impact of respiratory infections by preventing RSV-related illnesses, particularly in susceptible groups like infants and older adults. For instance, in October 2024, the UK Health Security Agency, a UK-based government body, reported that the number of tuberculosis (TB) cases in England rose by 10.7% year-over-year in 2023, climbing from 4,380 cases in 2022 to 4,850 cases. Therefore, the growing incidence of respiratory infections will fuel the growth of the respiratory syncytial virus vaccine market.
Respiratory Syncytial Virus Vaccine Market Segment Analysis And Revenue Potential
The respiratory syncytial virus vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Clinical Indications: Pediatric Indication, Geriatric Indication, High-Risk Individuals
3) By Distribution Channel: Hospital And Others Pharmacies, Government Suppliers
Respiratory Syncytial Virus Vaccine Market Trends Powering Strategic Industry Growth
Major companies in the respiratory syncytial virus (RSV) vaccine market are concentrating on developing innovative solutions, such as recombinant protein-based vaccine technologies, to meet the increasing demand for highly effective vaccines, better immune protection, and safer formulations for older adults who face a higher risk of RSV complications. Recombinant protein-based vaccines are developed using genetically engineered proteins that imitate viral components, allowing for powerful, targeted immune responses without employing a live virus, thus offering a more controlled and stable alternative to traditional vaccine methods. For instance, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, obtained FDA approval for Arexvy, which is the first RSV vaccine specifically designed to prevent lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy leverages advanced recombinant protein technology to target the RSV fusion (F) protein, a vital viral component necessary for infection, thereby delivering strong protection for older adults.
Respiratory Syncytial Virus Vaccine Market Key Players Shaping Industry Direction
Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, Moderna Inc.
View The Full Respiratory Syncytial Virus Vaccine Market Report:
Respiratory Syncytial Virus Vaccine Market Geographic Distribution And Regional Opportunities
North America was the largest region in the respiratory syncytial virus vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
